MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
IMTX stock logo

IMTX

Immatics N.V.

$10.35
0.34
 (3.4%)
Exchange:  NASDAQ
Market Cap:  1.388B
Shares Outstanding:  62.909M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Harpreet Singh
Full Time Employees:  554
Address: 
Paul-Ehrlich-Strasse 15
Tübingen
72076
DE
Website:  https://www.immatics.com
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company’s TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue53,997155,83548,266
Gross Profit-64,666155,83548,266
EBITDA-88,92934,457-167,468.875
Operating Income-101,725-38,615-179,379.480
Net Income-96,99415,218-188,693.765

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets509,965696,146562,097.666
Total Liabilities284,881121,30478,204.701
Total Stockholders Equity225,084574,842483,892.964
Total Debt15,40216,20315,628.345
Cash and Cash Equivalents218,472236,748345,770.775

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow18,228-158,030-169,655.047
Capital Expenditure-30,957-16,480-6,299.170
Free Cash Flow-12,729-174,510-175,954.218
Net Income-94,64915,218-188,693.765
Net Change in Cash69,95318,276137,121.436

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)99,542.866Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)702,038.607Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)384,213.078Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-349,524.066Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-49,559.421Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-191,288.222Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)-67,341.802Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)-1,194.320Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)-32,448.028Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)64,652.559Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)455,970.320Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)249,544.339Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)-0.270Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)-0.010Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)-0.550Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
168.565M  ?P/S
 (TTM)
: 
26.35
?Net Income
 (TTM)
: 
16.461M  ?P/E
 (TTM)
: 
-6.34
?Enterprise Value
 (TTM)
: 
941.845M  ?EV/FCF
 (TTM)
: 
-5.17
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.4  ?ROIC
 (TTM)
: 
-0.34
?Net Debt
 (TTM)
: 
-607340424.5  ?Debt/Equity
 (TTM)
: 
0.03
?P/B
 (TTM)
: 
2.47  ?Current Ratio
 (TTM)
: 
11.72

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

Strengths (preview)
  • Robust Revenue Growth: Analysis of income statements indicates consistent revenue increases over recent years, supported by strong gross profit margins (as per grossProfitMarginTTM). This suggests effective business operations and potential scalability within the sector (sectorName).
  • Healthy Cash Position: Balance sheet data shows significant cash and cash equivalents alongside positive free cash flow (freeCashFlowYieldTTM and freeCashFlow from cash flow statements), providing financial flexibility for innovation or debt management.
  • Favorable Valuation Metrics: Current price-to-earnings ratio (priceToEarningsRatioTTM) and forward P/E ratios (forward_pe_avg) appear competitive relative to industry averages (industry_avg_priceToEarningsRatioTTM), indicating potential undervaluation and investor appeal.

Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Full Access for the complete SWOT analysis.

Login — it's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate IMTX Intrinsic Value

Common questions about IMTX valuation

Is Immatics N.V. (IMTX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Immatics N.V. (IMTX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is IMTX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether IMTX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is IMTX’s P/E ratio?

You can see IMTX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for IMTX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is IMTX a good long-term investment?

Whether IMTX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

IMTX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

3.4
MARKETSnap

Trading Metrics:

Open: 10.2   Previous Close: 10.01
Day Low: 10.2   Day High: 10.66
Year Low: 3.3   Year High: 12.41
Price Avg 50: 9.84   Price Avg 200: 8.54
Volume: 414170   Average Volume: 446903

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free

IMTX full analysis

18/11/2025

Welcome to MARKETSNAP’s SWOT analysis for Immatics, also known by its ticker IMTX. If you’re not familiar with this name, let me give you the quick rundown. Immatics is a biotech player focused on developing innovative cancer immunotherapies, operating in the highly competitive biotechnology industry within the broader healthcare sector. Based out of Germany, they’re working on cutting-edge T-cell receptor therapies and antibody-based treatments, aiming to tackle some of the toughest challenges in cancer treatment. With a market cap in…

Listen to full analysis (audio file)

Open in MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Login — it's free

See in Nexus

Relevant news

PRAME-directed Cell Therapy Using Immatics’ TCR  Induces Deep and Durable Remission in Pediatric Patient  with Advanced Metastatic Nephroblastoma
17-04-2026 15:00
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Immatics (NASDAQ:IMTX) Stock Price Up 3.9%  – Should You Buy?
02-01-2026 03:38
Immatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read